Cipla Ltd Q4FY22 PAT down -12.4% at Rs362.07 crore yoy as EBITDA margins fall 279 bps to 14.5%

12 May 2022 , 01:55 AM

Cipla Ltd reported 14.19% growth in sales revenues yoy for the Q4FY22 quarter on consolidated basis at Rs5,260.33 crore. On a sequential basis, revenues were lower for the quarter by -3.99%.

For the full year FY22, the revenues were higher by 13.6% at Rs21,763 crore. For Q4FY22, Cipla saw a 16% growth in R&D spends. Its One-India initiative sustained momentum across core therapies growing by 21%.

The North American business also saw 17% dollar growth on focus on the core business and strong traction across respiratory portfolio as well as peptide unlocking. API business was down -41% yoy in dollar terms

The consolidated net profit for Q4FY22 was down -12.41% at Rs362.07 crore while it was down on a sequential basis by -50.31%.

The total debt has fallen sharply yoy from Rs1,756 crore to Rs824 crore. EBITDA was down -4% at Rs763 crore while EBITDA margins tapered by 279 basis points to 14.5%.

Net margins stood at 6.88% in Q4FY22 quarter compared to 8.97% in Q4FY21. NPM was lower sequentially against 13.3% in Q3FY22. Cipla has a total of 259 ANDAs and NDAs in its portfolio and its pipeline. API continued to show pressure.

Financial highlights for Mar-22 compared yoy and sequentially

	Cipla
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 5,260.33	₹ 4,606.45	14.19%	₹ 5,478.86	-3.99%
Net Profit (Rs cr)	₹ 362.07	₹ 413.38	-12.41%	₹ 728.60	-50.31%
Diluted EPS (Rs)	₹ 4.48	₹ 5.12		₹ 9.02
Net Margins	6.88%	8.97%		13.30%